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Background: The diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography
(18F-FDG PET/CT) as the first imaging approach in the evaluation of rising carcinoembryonic antigen (CEA) is not clear.
The objective of this study was to investigate the value of 18F-FDG PET/CT in patients with colorectal cancer (CRC) and
suspected recurrence based on rising CEA.
Methods: A total of 73 patients with CRC were referred to PET/CT after radical surgery. Generally, all patients were
scheduled to follow a CT-based post-surgical follow-up regimen. In the case of rising CEA, 18F-FDG PET/CT was
performed in most patients with contrast-enhanced CT. The PET/CT images were independently reviewed by two
readers. The presence or absence of recurrence was based on histology and/or standardized clinical follow-up.
Results: Among 35 patients who had confirmed recurrence of CRC, PET/CT demonstrated recurrence with a
sensitivity of 85.7 %, a specificity of 94.7 %, a positive predictive value of 93.8 %, and a negative predictive value
of 87.8 %. The SUVmax ranged from 1.3 to 19.9. The mean time since the last postoperative imaging and PET/CT
was 8 months (median 4 months). CEA values at referral ranged from 1.5 to 164.0 μg/L (median 5.6 μg/L). The
diagnostic properties of PET/CT were analyzed in subgroups of patients with a single rising CEA sample (30 patients,
41 %), 31 patients (43 %) with two or more consecutive increases, and 12 patients (16 %) with persistently elevated
values.
Conclusions: 18F-FDG PET/contrast-enhanced CT has high diagnostic accuracy in the diagnosis of recurrent CRC, even
in patients in a conventional CT-based follow-up program.
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Colorectal cancer (CRC) is the third most common can-
cer in the world. It is estimated that up to 40 % of
patients will present with recurrence after surgical resec-
tion of the primary tumor, often within 2 years [1].
Imaging plays a key role in the postoperative assessment
of recurrent disease. Most guidelines recommend com-
puted tomography (CT) at regular intervals, e.g. thora-
coabdominal CT at 12 and 36 months postoperatively as
well as upon clinical suspicion.* Correspondence: lajp@rn.dk
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(http://creativecommons.org/publicdomain/zeThe role of 18F-fluorodeoxyglucose positron emission
tomography/computed tomography (18F-FDG PET/CT)
in the follow-up of CRC patients is controversial. Recent
systematic reviews suggest no indication for 18FDG-PET/
CT except in cases of inconclusive CT [2, 3] or suspicion
of distant metastasis [4].
The role of CEA as a biomarker for imaging in CRC is
not clear. CEA is expressed in the majority of CRC cells
[5], but elevated CEA may be due to a variety of benign
and malignant conditions [6]. However, unexplained
rising CEA after surgery is a strong indicator of CRC
recurrence [7, 8]. A recent meta-analysis showed an
excellent sensitivity of 94 % and acceptable specificity of
77 % of 18F-FDG PET/CT for recurrent CRC in patients
with rising CEA [9].is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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presence of negative CT and serial CEA increases. The
role of CT as a gate-keeper for PET/CT is not clear.
It has been our institutional practice for years to per-
form 18FDG PET/CT as the first modality for clinical
suspicion of recurrent CRC based on rising or abnormal
CEA, i.e. without a prior CECT. Here we report excel-
lent diagnostic properties for 18FDG PET/CT, including
in patients with a recent CECT as part of routine follow
up. The details of CEA, i.e. the number of rises and the
CEA values at referral, were analyzed and showed value
of PET/CT among most patients.Methods
Patients
We retrospectively identified consecutive patients re-
ferred for PET/CT on the suspicion of recurrent CRC.
The patients had an 18F-FDG PET/CT scan performed
between January 1, 2006 and May 28, 2013 at our
department. The eligibility criteria were as follows: 1)
Histologically confirmed diagnosis of CRC, 2) pathology-
verified radical surgery, 3) suspicion of recurrent CRC
due to at least one rising CEA or CEA above upper limit
of normal. Patients referred for PET/CT due to negative
or inconclusive results of prior imaging performed due
to clinical suspicion (not routine scans as part of follow
up programs) were excluded. If eligible patients had
more than one PET/CT due to rising CEA, only the first
procedure was included in the analysis. A few patients
were treated with non-surgically, e.g. by radiofrequency
ablation of synchronous or metachronous liver metasta-
sis and considered curatively treated based on clinical
and imaging follow-up.Postoperative surveillance program
Most patients (>85 %) followed a standardized post-
operative follow-up program, which included CT 12 and
36 months postoperatively. A total of 18 of the patients
participated in the COLOFOL study [10], of which 9 pa-
tients received standard CT follow up, and 9 patients
had CT scheduled at 6, 12, 18, 24 and 36 months.CEA
The measurement of serial CEA levels was integrated in
the post-surgical monitoring. The time intervals between
CEA measurements varied among patients due to indi-
vidual baseline CEA, CEA doubling time, or CEA vel-
ocity (increase in μg/L per time unit). Thus, no definite
CEA cut-off value was required for referral for PET/CT.
Patients were divided into quartiles based on CEA levels.
The upper limit of normal for CEA was 3.0 μg/L for
non-smokers (n = 65) and 10.0 μg/L for smokers (n = 8).Imaging procedure and evaluation
Whole-body images were obtained by PET/CT (Discovery
VCT, GE Healthcare) in accordance with institutional pro-
cedures. The mean dose was 379 MBq of 18F-FDG. Blood
glucose levels were less than 11 mmol/L in all patients.
The PET/CT scan was acquired approximately 60 min
after tracer injection. Low-dose CT was acquired in 9
(12 %) patients, and diagnostic CT with intravenous iodin-
ated contrast was performed in 64 patients (88 %). Most
of the latter patients received 100 ml of Iomeron® 400 mg
iodine/mL (n = 52).
Due to inconsistent reporting of maximum standard-
ized uptake values (SUVmax) in clinical study reports, all
images were independently reviewed by two radiologists
with solid experience with PET/CT. Any discrepancy in
diagnosis among the readers was solved by consensus.
The readers were aware of the clinical history and
laboratory results at referral but blinded to the original
PET/CT report, clinical follow-up, and pathology re-
ports. The classification of lesions as malignant or be-
nign on PET/CT was based on combined parameters
from both PET and CT. The readers did not report the
diagnostic outcome for each modality separately. In a
few cases, the PET/CT was classified as malignant based
on CT findings only, e.g. small pulmonary nodules.
Definition of recurrence
The presence or absence of recurrent CRC was deter-
mined based on histopathological examination or follow
up. In the absence of positive pathology, we aimed at a
clinical follow up of at least 24 months of observation
with conventional imaging modalities showing progres-
sion in measurable lesions by RECIST criteria, or by an
adequate response to therapeutic interventions to clarify
recurrent CRC. The absence of disease was established if
no malignancy could be detected with available informa-
tion regarding additional imaging, serial physical exami-
nations including laboratory quantities and regular
endoscopy without abnormalities. The results were per-
formed on a patient basis.
Statistical analysis
Data were described by mean or median with total
range and proportions. Statistical analysis was per-
formed using Chi square test using GraphPad Prism
version 6.05 (GraphPad Software, Inc., California,
USA). Two-sided p-values <0.05 were considered statis-
tically significant.
Ethical approval and consent
This retrospective study did not require ethical approval
or informed consent in accordance with national legisla-
tion. The study was approved by the Danish Data Pro-
tection Agency who provided waiver for informed
Table 1 Patient demographics and baseline information
Number of patients 73
Males 41 (56 %)
Females 32 (44 %)
Mean age, years (range) 65 (44–86)
Adenocarcinoma localization
Caecum 6 (8 %)
Caecum and ascending colon 1 (≈1 %)
Ascending colon 4 (5 %)
Transverse colon 5 (7 %)
Descending colon 1 (≈1 %)
Sigmoid colon 13 (18 %)
Rectum 43 (59 %)
Primary tumor, pathological stage
T1 5 (7 %)
T2 11 (15 %)
T3 39 (53 %)
T4 16 (22 %)
TX 2 (3 %)
Lymph node involvement, pathological stage
N0 41 (56 %)
N1 18 (25 %)
N2 13 (18 %)
NX 1 (≈1 %)
Neoadjuvant therapy
No 61 (84 %)
Yes 12 (16 %)
Adjuvant chemotherapy
No 51 (70 %)
Yes 22 (30 %)
Time since last curative surgery and PET/CT scan
<6 months 7 (10 %)
6–12 months 10 (14 %)
12–18 months 16 (22 %)
18–24 months 14 (19 %)
24–36 months 14 (19 %)
>36 months 12 (16 %)
Time since last postoperative imaging and PET/CT scan
<3 months 22 (30 %)
3–6 months 14 (19 %)
6–12 months 15 (21 %)
>12 months 12 (16 %)
No postoperative imaging 10 (14 %)
Last postoperative imaging modality before PET/CT scan
CT 55 (75 %)
MRI 4 (5 %)
Table 1 Patient demographics and baseline information
(Continued)
PET/CT (not due to increasing CEA) 4 (5 %)
No postoperative imaging 10 (14 %)
CEA subgroups
1 increase in CEA 30 (41 %)
2 consecutive increases in CEA 26 (36 %)
>2 consecutive increases in CEA 5 (7 %)
Persistently elevated CEA 12 (16 %)
PET/CT positron emission tomography/computed tomography, MRI magnetic
resonance imaging, CEA carcinoembryonic antigen
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findings.Results
Patients
The final study population consisted of 73 patients
(Table 1). The histology showed adenocarcinoma in all
patients. In addition to surgery, eight patients received
additional curative intervention for synchronous metas-
tasis (n = 6) or metachronous metastasis (n = 2). The
mean time since curative surgery and the PET/CT scan
was 24 months (range 2–84 months). The mean time
between the measurement of CEA and the PET/CT scan
was 34 days (range 8–111 days). Thirty-five patients
(48 %) had a recurrence of CRC of which 25 were con-
firmed by pathology and 10 by clinical follow-up. Thirty
patients were followed without criteria for recurrent
CRC for at least 24 months. Six patients were observed
for 14–19 months without indications of recurrent dis-
ease. Two patients died within 24 months of PET/CT
due to non-CRC cancer.Imaging evaluation
The PET/CT was positive for CRC in 32 patients (44 %)
and negative in 41 patients (56 %). The readers showed
substantial agreement in their assessment with agree-
ment in 89 % of the cases (Cohen’s kappa 0.778). A total
of 41 malignant lesions were identified with a mean
SUVmax of 8.6 (range 1.3–19.9). The distribution of FDG
lesions assessed as positive for recurrent CRC is shown
in Table 2. The term “other locations” included seven
FDG-positive lesions located in distant lymph nodes (2
cases), abdominal wall (2), peritoneal carcinosis (2), and
the top of the vagina. Most PET/CT positive lesions
have SUVmax >5 (n = 33). In comparison to other re-
gions, pulmonary lesions were frequently small with half
of them with SUVmax <5. Two patients had malignant
infiltrates in the lungs on CT below the detection limit
of PET.
Table 2 Distribution of SUVmax assessed as positive for recurrent CRC on PET/CT
Anatomical area
Local Locoregional Hepatic Pulmonary Other locations All locations
SUVmax mean (range) 7.8 (2.9–18.8) 8.3 (6.2–10.0) 10.0 (3.3–19.9) 5.5 (1.3–13.3) 12.0 (8.1–19.5) 8.6 (1.3–19.9)
Lesions, number 8 7 10 9 7 41
SUVmax ≤2.5 0 0 0 2 0 2
SUVmax >2.5/<5.0 2 0 2 2 0 6
SUVmax ≥5.0 6 7 8 5 7 33
SUVmax maximum standardized uptake value
Fig. 1 Patient-based PET/CT outcome and CRC recurrence in
relation to time since the last postoperative imaging. The population
was subdivided into five groups: <3 months since imaging (n = 22),
3–6 months since imaging (n = 14), 6–12 months since imaging
(n = 15), >12 months since imaging (n = 12) and no postoperative
imaging (n = 10). White boxes: PET/CT-positive, black boxes: Verified
CRC recurrence
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With regard to recurrent CRC, there were 30 true posi-
tive and 36 true negatives cases, two were false positive,
and five were false negative cases, resulting in a PET/CT
sensitivity of 85.7 % and specificity of 94.7 %. The posi-
tive predictive value (PPV) was 93.8 %, and the negative
predictive value (NPV) was 87.8 %.
The two false positive cases were due to inflammation.
Both patients were referred with a single rising CEA (3.1
and 5.2 μg/L).
Five false negative cases were observed by PET/CT of
which four patients were positive for CRC by subsequent
pathology performed 6–24 months after PET/CT (median
15 months). Two patients had one rising CEA (5.1 and
5.9 μg/L) and confirmed pulmonary metastases. Two pa-
tients had two consecutive increases in CEA (peak 4.4 and
5.9 μg/L) with liver metastases and pelvic recurrence, re-
spectively. One patient had persistently elevated CEA
(5.8 μg/L) and presented with liver metastases.
Prior imaging
Almost one-third of the patients had post-operative im-
aging within three months from the actual PET/CT
(Table 1) with a median time of 4 months (range <1–59
months). Most prior investigations were contrast-
enhanced CT. The outcome of PET/CT versus the time
since the last post-operative imaging is shown in Fig. 1.
PET/CT was the first post-operative imaging modality
after surgery in ten patients. There was no significant dif-
ferences in PET/CT positivity (p = 0.18) or confirmed
CRC (p = 0.16) with increasing time since last imaging;
there was no significant differences in PET/CT sensitivity
(73–100 %, p = 0.47) or specificity (89–100 %, p = 0.71)
with time since last imaging.
CEA
The diagnostic properties of PET/CT were analyzed in
subgroups of patients with rising or elevated CEA
(Table 3). The median CEA was 5.6 μg/L (range 1.5–
164.0). There were a notable number of PET/CT posi-
tive patients and patients with confirmed CRC among
patient with 1, 2, and >2 CEA increases as well as among
patient with persistently elevated CEA. There was asignificant difference among the proportion of patients with
a positive PET/CT (p = 0.02) among these groups, but no
clear statistical difference in confirmed CRC (p = 0.26).
The impact of the CEA level at referral is shown in
Fig. 2. The patients were divided into quartiles. The me-
dian CEA levels in the four quartiles were: Q1 (4.0 μg/L,
n = 19), Q2 (5.1 μg/L, n = 18), Q3 (6.1 μg/L, n = 18), and
Q4 (13.1 μg/L, n = 18). The data confirmed a significant
association of CEA level with a positive PET/CT out-
come (p = 0.04) and recurrent CRC (p = 0.01).
Diagnostic properties of 18F-FDG PET/CT for the de-
tection of recurrent CRC were calculated in the divided
CEA subgroups and quartiles (Table 4). There were no
significant differences with regards to sensitivity or spe-
cificity among CEA types (p-values 0.60 and 0.38) or
quartiles (p-values 0.26 and 0.21). PPV as well as NPV
was excellent in patients with the highest CEA levels at
referral (Q3 and Q4), but of clinical interest also in pa-
tients with lower CEA levels. PPV was excellent in all
types of CEA increases but 1 single rise. Figure 3 shows
Table 3 PET/CT outcome and CRC recurrence in CEA subgroups
CEA subgroups
1 increase (n = 30) 2 increases (n = 26) >2 increases (n = 5) Persistently elevated (n = 12)
Number of PET/CT-positive patients 19 (63 %) 7 (27 %) 3 (60 %) 3 (25 %)
Number of patients with CRC recurrence 18 (60 %) 10 (38 %) 3 (60 %) 4 (33 %)
Median CEA, μg/L 6.75 4.85 4.0 5.7
CEA range, μg/L 1.7–164.0 2.3–16.4 1.5–6.1 3.4–7.8
PET/CT positron emission tomography/computed tomography, CRC colorectal cancer, CEA carcinoembryonic antigen
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recurrent CRC.
Diagnosis of non-CRC malignancies
Two patients were PET/CT positive for primary lung
cancer as confirmed by pathology. Furthermore, one pa-
tient was categorized as PET/CT positive for both recur-
rent CRC (liver metastasis) and primary lung cancer,
with both lesions confirmed by pathology. Two of these
patients were referred with one rising CEA (7.0 and
42.7 μg/L) and one patient had two consecutive in-
creases in CEA (peak 16.4 μg/L). The diagnostic proper-
ties of 18F-FDG PET/CT for any malignancy (CRC and
non-CRC) showed a sensitivity of 86.5 %, a specificity of
91.9 %, a PPV of 94.1 %, and an NPV of 87.2 %.
Discussion
It has been our institutional practice to perform 18F-FDG
PET/CT as the first imaging on suspicion of recurrent
CRC due to unexplained rising CEA. If prior imaging was
performed approximately more than one month ago, it
was institutional practice to perform the PET/CT withFig. 2 Patient-based PET/CT outcome and CRC recurrence in
relation to CEA quartiles. The population was subdivided into four
groups: Group Q1 (n = 19), below the first quartile; group Q2 (n = 18),
between the first quartile and the median; group Q3 (n = 18), between
the median and the third quartile; and group Q4 (n = 18), above the
third quartile. White boxes: PET/CT-positive, black boxes: Verified
CRC recurrencecontrast-enhancement. The results showed excellent sen-
sitivity and specificity as well as predictive values for
recurrent CRC in a largely asymptomatic population. This
retrospective study included a rigorous selection of eligible
patients from a 7-year consecutive population. Curative
surgery was validated by records and pathology speci-
mens. Strict and specific criteria for the presence or
absence of recurrent CRC were applied. PET/CT, mostly
performed with contrast-enhancement, were independ-
ently evaluated with substantial agreement by two readers
blinded to any clinical, laboratory or pathology data accu-
mulated after the date of PET/CT. Our study demon-
strated excellent diagnostic accuracy of 18F-FDG PET/CT
as the primary imaging tool in patients with rising CEA
and suspicion of recurrent CRC.
The value of follow-up of CRC has been questioned for
years, including the value of scheduled and clinical re-
quired visits [11]. A recent prospective, non-randomized
study demonstrated that the majority of patients with
recurrent CRC were identified at scheduled visits in a
strict follow-up program. In that trial, CT and FDG-PET
combined had better diagnostic properties than other
imaging modalities [12]. A very recent randomized trial
with more than 1,200 patients showed no benefit of com-
bining serial CEA measurements with CT versus CT or
CEA alone [13]. Our results indicated a high sensitivity
and specificity of 18F-FDG PET/CT in detecting recurrent
CRC, largely regardless of CEA levels and the level of
CEA increases. These data are largely in line with findings
from other retrospective studies [14–17]. We are only
aware of one prior study of PET/CT as the first imaging
on suspicion on recurrent CRC [18]. That study required
CEA levels above 5.0 μg/L, provided limited information
about the research methodology, but it showed diagnostic
outcome similar to our data.
A notable proportion of patients with negative findings
on routine CT performed within 3 to 6 months of refer-
ral presented with a positive PET/CT. Even though this
study was not a comparison of CT vs. PET/CT, these
findings are in line with several studies. A number of
studies have compared 18FDG PET/CT and conventional
CT in patients with increasing or elevated CEA and have
shown a better overall detection rate for PET/CT [19]
and higher sensitivity [20]. Our findings of recurrent
Table 4 18F-FDG PET/CT in the detection of CRC recurrence in patients with different CEA patterns
PET/CT diagnostic properties
Sensitivity Specificity PPV NPV
CEA quartiles Q1 (n = 19) 100.0 % 92.9 % 83.3 % 100.0 %
Q2 (n = 18) 75.0 % 90.0 % 85.7 % 81.8 %
Q3 (n = 18) 70.0 % 100.0 % 100.0 % 72.7 %
Q4 (n = 18) 100.0 % 100.0 % 100.0 % 100.0 %
CEA rise type 1 increase (n = 30) 94.4 % 83.3 % 89.5 % 90.9 %
2 increases (n = 26) 70.0 % 100.0 % 100.0 % 84.2 %
>2 increases (n = 5) 100.0 % 100.0 % 100.0 % 100.0 %
Persistently elevated (n = 12) 75.0 % 100.0 % 100.0 % 88.9 %
18F-FDG PET/CT 18F-fluorodeoxyglucose positron emission tomography/computed tomography, CRC colorectal cancer, CEA carcinoembryonic antigen, PPV positive
predictive value, NPV negative predictive value
Fig. 3 Illustrative example of PET/CT for the detection of recurrent CRC. A 54-year-old man with adenocarcinoma in the sigmoid colon (pT4, pN2,
M0) received three cycles of neoadjuvant chemotherapy followed by radical surgery in May 2010 and five cycles of adjuvant chemotherapy. The
patient presented with one significant increase in CEA from 1.4 μg/L (May 2011) to 5.1 μg/L (November 2011), and he underwent an 18F-FDG PET/CT
scan with low-dose CT. Intraabdominal as well as retroperitoneal lymph nodes were found to exhibit pathological FDG uptake (SUVmax = 8.1), especially
at foci near the liver hilus and portacaval area (PET anterior view (a); CT coronal image (b); PET/CT coronal fused image (c). The patient had recurrence
on the basis of radiological and clinical follow-up and died shortly after the study period. A conventional CT scan of the thorax, abdomen and pelvis in
usual surveillance was carried out 41 days earlier with no evidence of recurrence or metastasis
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tine CT is interesting, but the data do not allow us to
conclude that PET/CT is superior to conventional CT.
Recurrent CRC was found in approximately 50 percent
of our study population, and PET was positive in the
majority of the patients. However, we did not include
patient without any rise of CEA. So it would not be
appropriate to claim superiority of PET over CEA for
the detection of recurrent CRC. The role of CEA as
gatekeeper can be discussed. Makis et al., identified 99
patients with true positive PET for recurrent CRC of
which only 65 patients presented with elevated CEA
[21]. In contrast, in a small study with some methodo-
logical concerns, Amin et al., found only 1 in every 10
patients with unexplained rising CEA to have a true
positive PET for CRC [22]. In summary, even though
unexplained rising CEA is not a specific biomarker for
recurrent CRC [6], CEA will likely still be considered a
valuable biomarker and gatekeeper for PET.
The proportion of positive PET/CT findings and veri-
fied CRC recurrence increased with absolute CEA levels,
which is consistent with prior studies [19, 23]. It could
be debated if an absolute value of CEA should be re-
quired for referral for PET/CT [17, 21]. A recent meta-
analysis showed upper limits of normal in the original
papers ranged from 3 to 15 μg/L [24]. Tan et al., sug-
gested a cut-off of 2.2 μg/L to demonstrate a high speci-
ficity (90 %) though limited sensitivity (64 %) for the
diagnosis of recurrent CRC [24]. Most of our patients
presented with absolute CEA levels above of the upper
limit of 3 μg/L, the institutional upper limit of normal
for non-smokers. Our data do not allow us to draw
conclusions about the role of PET/CT in patients with
normal levels of CEA. However, other reports have doc-
umented PET-positive, confirmed CRC recurrence in
patients with normal CEA values [21].
In addition to the absolute CEA levels, the pattern of
CEA rise is relevant to consider. The National Compre-
hensive Cancer Network considers serial CEA increases
as an indication for workup for recurrence [25]. The ad-
vantages of serial versus single CEA increases have been
reviewed by Goldstein et al. [6]. It was documented that
serial measurements are more effective than clinical
evaluation or other diagnostic modalities in postopera-
tive detection of patients with metastatic disease, with
the highest sensitivity for liver metastases. However,
there are conflicting data about the diagnostic role of
serial versus single CEA elevations [26, 27]. We identi-
fied a notable proportion of patients with recurrent CRC
with 1, 2, >2 or persistently elevated CEA levels. Among
our patients, the median CEA at referral was higher
(and with a much broader range) in patients with one
increase than in patients with two measurements. This
may explain the low rate of positive PET/CT scans inthe latter group. The time intervals between CEA mea-
surements should also be considered. Patients with a
single large increase in CEA may be referred directly for
PET whereas a minor increase led to referral only when
the increasing trend has been confirmed. Thus we be-
lieve that 18F-FDG PET/CT can be usefully used as first
imaging based on unexplained rising CEA, provided that
CEA measurement and interpretation is consistent with
individual patient’s clinical situation.
We are aware of methodological issues with this study,
mostly related to the retrospective nature of the study.
This includes variability in the time since surgery, time
and type of the latest diagnostic imaging before PET/CT,
CEA measurements, and the risk of recurrence after
surgery. However, we applied strict criteria for the defi-
nitions of curative surgery, PET/CT scans were blindly
re-read with consistency among readers, and there was
adequate follow up in all patients. Lastly, most patients
with recurrent CRC were biopsy-proven. The 24 month
clinical observation period was selected since it was ob-
served that a number of patients presented with biopsy-
proven CRC between 1 and 2 years after the PET/CT.
We are aware of the potential bias of a long time inter-
val from PET/CT to a final diagnosis. A disease classifi-
cation based on histopathology or clinical follow-up
2 years after imaging may false classify some patients as
false negative, although they could be true negative at
the time of the PET/CT scan.Conclusions
We conclude that 18F-FDG PET/CT have high diagnostic
value and can be used as the first choice in the detection
of recurrent CRC in patients with unexplained rising
CEA, even in patients with a recent normal routine CT.Abbreviations
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